Table 3.
Risk of neutropenia in cycles 1–2 by clinical characteristics.
| Patient characteristics, N (%) | No neutropenia (n = 41) | Any grade neutropenia (n = 155) | Odds ratio (95% CI) | p Value | Grade 0–2 NTP (n = 129) | Grade 3–4 NTP (n = 67) | Odds ratio (95% CI) | p Value |
|---|---|---|---|---|---|---|---|---|
| Age in years | ||||||||
| <50 | 13 (32%) | 47 (30%) | — | 0.9855 | 38 (29%) | 22 (33%) | — | 0.6806 |
| 50–69 | 21 (51%) | 81 (52%) | 1.07 (0.48–2.33) | 70 (54%) | 32 (48%) | 0.79 (0.40–1.55) | ||
| ≥70 | 7 (17%) | 27 (18%) | 1.07 (0.38–3.00) | 21 (16%) | 13 (19%) | 1.07 (0.45–2.55) | ||
| Sex | ||||||||
| Male | 26 (63%) | 61 (39%) | — | 0.0059 | 68 (53%) | 19 (28%) | — | 0.001 |
| Female | 15 (37%) | 94 (61%) | 2.67 (1.48–3.71) | 61 (47%) | 48 (72%) | 2.82 (1.49–5.31) | ||
| Race | ||||||||
| Black | 1 (2%) | 11 (7%) | — | 0.4263 | 7 (5%) | 5 (7%) | — | 0.2264 |
| White | 36 (88%) | 133 (86%) | 0.33 (0.04–2.69) | 115 (90%) | 54 (81%) | 0.66 (0.20–2.1) | ||
| Other | 4 (10%) | 11 (7%) | 0.25 (0.02–2.61) | 7 (5%) | 8 (12%) | 1.60 (0.35–7.40) | ||
| BMIa | ||||||||
| <Median | 16 (40%) | 80 (52%) | — | 0.1768 | 59 (46%) | 37 (56%) | — | 0.188 |
| ≥Median | 24 (60%) | 74 (48%) | 0.62 (0.30–1.25) | 69 (54%) | 29 (44%) | 0.67 (0.37–1.22) | ||
| ECOG performance status | ||||||||
| 0 | 18 (44%) | 104 (67%) | — | 0.0072 | 76 (59%) | 46 (67%) | — | 0.1791 |
| 1 | 23 (56%) | 51 (33%) | 0.38 (0.19–0.77) | 53 (41%) | 21 (31%) | 0.65 (0.35–1.22) | ||
| # Prior lines of therapy | ||||||||
| 0 | 6 (15%) | 18 (12%) | — | 0.5859 | 17 (13%) | 7 (11%) | — | 0.4799 |
| 1 | 9 (22%) | 43 (28%) | 1.59 (0.49–5.13) | 37 (29%) | 15 (22%) | 0.98 (0.34–2.86) | ||
| 2 | 8 (19%) | 19 (12%) | 0.79 (0.22–2.73) | 19 (15%) | 8 (12%) | 1.02 (0.31–3.42) | ||
| ≥3 | 18 (44%) | 75 (48%) | 1.39 (0.48–4.00) | 56 (43%) | 37 (55%) | 1.60 (0.61–4.25) | ||
| Immediate prior line chemotherapy | ||||||||
| No | 30 (73%) | 91 (59%) | — | 0.0843 | 79 (61%) | 42 (63%) | — | 0.8432 |
| Yes | 11 (27%) | 64 (41%) | 1.91 (0.90–4.11) | 50 (39%) | 25 (37%) | 0.94 (0.51–1.73) | ||
| Baseline ANC | ||||||||
| <Median | 4 (10%) | 90 (58%) | — | <0.0001 | 44 (34%) | 50 (75%) | — | <0.0001 |
| ≥Median | 37 (90%) | 65 (42%) | 0.08 (0.03–0.23) | 85 (66%) | 17 (25%) | 0.18 (0.09–0.34) | ||
| Trial | ||||||||
| Basket Trial | 32 (78%) | 105 (68%) | — | 0.1906 | 87 (67%) | 50 (75%) | — | 0.2942 |
| Sarcoma Trial | 9 (22%) | 50 (32%) | 1.69 (0.75–3.82) | 42 (33%) | 17 (25%) | 0.70 (0.36–1.37) | ||
| Breast cancer | ||||||||
| No | 36 (88%) | 99 (64%) | — | 0.0017 | 99 (77%) | 36 (53%) | — | 0.0011 |
| Yes | 5 (12%) | 56 (36%) | 4.07 (1.51–10.97) | 30 (23%) | 31 (46%) | 2.84 (1.51–5.34) | ||
ANC absolute neutrophil count, BMI body mass index, ECOG Eastern Cooperative Oncology Group, NTP neutropenia.
aHeight missing from two patients (one patient with no NTP, one with grade 3 NTP).